Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
申请人:Merck & Co., Inc.
公开号:EP0611003B1
公开(公告)日:1997-06-18
US5451677A
申请人:——
公开号:US5451677A
公开(公告)日:1995-09-19
Substituted phenyl sulfonamides as selective .beta. 3 agonists for the
申请人:Merck & Co., Inc.
公开号:US05451677A1
公开(公告)日:1995-09-19
Substituted phenylsulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted alkyl epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.